Epoch Investment Partners Inc. lessened its position in shares of Alkermes PLC (NASDAQ:ALKS) by 3.7% in the third quarter, according to its most recent filing with the SEC. The firm owned 167,949 shares of the company’s stock after selling 6,442 shares during the quarter. Epoch Investment Partners Inc. owned approximately 0.11% of Alkermes worth $8,539,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Atlantic Trust Group LLC increased its position in Alkermes by 4.9% during the 2nd quarter. Atlantic Trust Group LLC now owns 167,717 shares of the company’s stock valued at $9,722,000 after purchasing an additional 7,807 shares during the period. Bank of New York Mellon Corp increased its position in Alkermes by 1.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 1,377,593 shares of the company’s stock valued at $79,859,000 after purchasing an additional 23,506 shares during the period. Tredje AP fonden increased its position in Alkermes by 85.5% during the 2nd quarter. Tredje AP fonden now owns 30,510 shares of the company’s stock valued at $1,769,000 after purchasing an additional 14,060 shares during the period. Legal & General Group Plc increased its position in Alkermes by 10.2% during the 2nd quarter. Legal & General Group Plc now owns 654,744 shares of the company’s stock valued at $37,956,000 after purchasing an additional 60,624 shares during the period. Finally, Aviva PLC increased its position in Alkermes by 5.4% during the 2nd quarter. Aviva PLC now owns 88,159 shares of the company’s stock valued at $5,111,000 after purchasing an additional 4,525 shares during the period. 99.69% of the stock is owned by institutional investors and hedge funds.

A number of equities analysts have issued reports on ALKS shares. Mizuho set a $81.00 price target on Alkermes and gave the stock a “buy” rating in a report on Saturday, October 21st. ValuEngine cut Alkermes from a “hold” rating to a “sell” rating in a report on Monday, October 23rd. UBS set a $54.00 price target on Alkermes and gave the stock a “hold” rating in a report on Friday, October 27th. Credit Suisse Group cut their price target on Alkermes from $70.00 to $66.00 and set an “outperform” rating on the stock in a report on Friday, October 27th. Finally, Barclays set a $50.00 price target on Alkermes and gave the stock a “hold” rating in a report on Thursday, October 26th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have issued a buy rating to the company’s stock. Alkermes presently has an average rating of “Hold” and an average target price of $63.55.

In related news, SVP James M. Frates sold 20,932 shares of the stock in a transaction on Wednesday, November 8th. The stock was sold at an average price of $47.58, for a total value of $995,944.56. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Richard F. Pops sold 50,000 shares of the stock in a transaction on Thursday, November 2nd. The stock was sold at an average price of $48.87, for a total value of $2,443,500.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 122,930 shares of company stock worth $6,051,110. 5.34% of the stock is owned by company insiders.

Alkermes PLC (ALKS) opened at $52.76 on Thursday. Alkermes PLC has a twelve month low of $46.42 and a twelve month high of $63.40. The company has a debt-to-equity ratio of 0.23, a quick ratio of 2.72 and a current ratio of 3.05.

Alkermes (NASDAQ:ALKS) last issued its earnings results on Thursday, October 26th. The company reported $0.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.04. Alkermes had a negative return on equity of 7.27% and a negative net margin of 20.12%. The company had revenue of $217.40 million for the quarter, compared to analysts’ expectations of $231.29 million. During the same period last year, the business earned ($0.09) EPS. Alkermes’s quarterly revenue was up 20.6% compared to the same quarter last year. equities research analysts anticipate that Alkermes PLC will post -0.59 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Epoch Investment Partners Inc. Sells 6,442 Shares of Alkermes PLC (ALKS)” was first published by Watch List News and is owned by of Watch List News. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The original version of this piece can be viewed at https://www.watchlistnews.com/epoch-investment-partners-inc-sells-6442-shares-of-alkermes-plc-alks/1748853.html.

Alkermes Company Profile

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

Want to see what other hedge funds are holding ALKS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alkermes PLC (NASDAQ:ALKS).

Institutional Ownership by Quarter for Alkermes (NASDAQ:ALKS)

Receive News & Ratings for Alkermes PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.